TerrAscend Corp. (CSE: TER; OTC) the first and only cannabis company licensed for sales in Canada , the US, and the EU, today announced that it has completed its first international shipment of dry cannabis flower to its German distribution partner iuvo Therapeutics GmbH ("iuvo"). The shipment was made from TerrAscend's EU GMP certified manufacturing facility in Mississauga, Ontario , Canada. As the Company ships additional product to Germany in partnership with iuvo, it will continue to expand its footprint in Europe and other international markets. The Company looks forward to providing investors with updates on such expansion activities.
"We look forward to bringing TerrAscend's quality products to the German market and working with a partner who is also focused on patient well-being," said Robyn Rabinovich , VP, Cannabis Strategy and Partnerships, "This first shipment solidifies our partnership with iuvo and will allow for ongoing access to high quality medical cannabis products for German patients."
"We are pleased to commence our first shipment to Germany together with our partner TerrAscend." Said Daniel Seidi , Director and Co-Founder of iuvo "In close collaboration we have successfully established a fully EU GMP/GDP licenced supply-chain of our pharmaceuticals. This places us in a unique position to respond to the supply-deficiency within the EU in the interest of the patients in need."
"We look forward to bringing TerrAscend's quality products to the German market and working with a partner who is also focused on patient well-being," said Robyn Rabinovich , VP, Cannabis Strategy and Partnerships, "This first shipment solidifies our partnership with iuvo and will allow for ongoing access to high quality medical cannabis products for German patients."
"We are pleased to commence our first shipment to Germany together with our partner TerrAscend." Said Daniel Seidi , Director and Co-Founder of iuvo "In close collaboration we have successfully established a fully EU GMP/GDP licenced supply-chain of our pharmaceuticals. This places us in a unique position to respond to the supply-deficiency within the EU in the interest of the patients in need."